Higher doses reached that plateau later in the trial. In a 112-week step-down trial, participants maintained 21.9% loss on the top dose, 16.6% after stepping down to 5 mg, and 9.9% on placebo
RESEARCH STUDIES BPC-157 Research Applications & Published Studies BPC-157 research spans more than two decades of published preclinical literature
But if youre comparing it to the data we have on GLP-1s, its not even in the same conversation
Youll receive expert guidance from your care team, helpful resources to track your progress, and support every step of the way
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Kolovrat M., Gojkovic S., Krezic I., Malekinusic D., Vrdoljak B., Kasnik Kovac K., Kralj T., Drmic D., Barisic I., Horvat Pavlov K., et al